Literature DB >> 32196117

Synovial Sarcoma: A Series of Small Tumors in Active Duty Service Members.

Taylor Bates1, Erica Kao2, Joseph Alderete1, Dustin Lybeck1.   

Abstract

Synovial Sarcoma is a soft tissue sarcoma with a propensity to imitate a benign neoplasm. It is most common in males 15-40 years old, typically presents as a slow growing painful mass, and often arises insidiously without alarm to the patient. Three patients with synovial sarcomas who had each undergone an index procedure to treat a small presumedly benign mass that was later identified as synovial sarcoma were reviewed. All three patients required re-excision of the tumor and tumor bed and are currently undergoing routine surveillance. All patients exhibited the classic translocation t(X;18) (p11.2; q11.2) and all were of the monophasic type. All lesions were less than 35 mm in greatest longitudinal dimension on MRI. None have experienced recurrences of synovial sarcoma to date. Healthcare providers should be aware of the synovial sarcoma's propensity to masquerade as a benign disease and the characteristic clinical and radiological findings. We advocate for a low threshold to obtain advanced imaging and consideration of a tissue diagnosis prior to excision. A referral to an orthopedic oncologist should be considered and biopsy should only be performed where the definitive treatment will take place if malignancy is identified. Published by Oxford University Press on behalf of the Association of Military Surgeons of the United States 2020. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Mesh:

Year:  2020        PMID: 32196117     DOI: 10.1093/milmed/usaa048

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  1 in total

1.  The safety of primary surgical excision of small deep indeterminate musculoskeletal soft tissue masses.

Authors:  Michèle Calleja; Qasim Afzaal; Asif Saifuddin
Journal:  Br J Radiol       Date:  2020-10-30       Impact factor: 3.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.